Blog
RSS FeedPosted by Michael Wonder on 04 Aug 2024
First time-limited reimbursement recommendation supports earlier patient access to a promising cancer treatment
30 July 2024 - Patients in Canada with advanced-stage lymphoma are one step closer to accessing the first drug to receive ...
Posted by Michael Wonder on 11 Jul 2023
Pluvicto receives positive recommendations from CADTH and INESSS for progressive PSMA positive metastatic castration-resistant prostate cancer
10 July 2023 - Health technology assessment agencies reinforce the therapeutic value of Pluvicto and need for new approaches to treat ...
Posted by Michael Wonder on 20 Apr 2023
Rybrevant (amivantamab) receives positive CADTH reimbursement recommendation for the treatment of adult patients with non-small cell lung cancer with activating EGFR exon 20 insertion mutations
6 April 2023 - This CADTH recommendation is a step towards public access to Rybrevant as a targeted therapy for ...
Posted by Michael Wonder on 01 Nov 2022
Verzenio (abemaciclib) receives positive reimbursement recommendation from CADTH for early breast cancer
1 November 2022 - Lilly Canada announced today that CADTH has issued their final reimbursement recommendation for Verzenio (abemaciclib) in ...
Posted by Michael Wonder on 05 Oct 2022
Tecentriq (atezolizumab) receives CADTH reimbursement recommendations for the adjuvant treatment of early-stage non-small-cell lung cancer and the treatment of extensive stage small cell lung cancer
5 October 2022 - The CADTH recommendations are a step towards public funding of this treatment option for some patients with ...
Posted by Michael Wonder on 26 Aug 2021
AbbVie receives a positive reimbursement recommendation from the Canadian Agencies for Drugs and Technology in Health (CADTH) pan-Canadian Oncology Drug Review Expert Review Committee (pERC) for Venclexta (venetoclax) in combination with azacitidine for acute myeloid leukaemia patients
26 August 2021 - pERC recommends reimbursement of Venclexta (venetoclax) in combination with azacitidine for the treatment of newly diagnosed acute ...
Posted by Michael Wonder on 04 May 2021
GSK’s Zejula is recommended for reimbursement by CADTH and INESSS for advanced ovarian cancer following response to first-line platinum-based chemotherapy
4 May 2021 - Zejula (niraparib) has received conditional positive recommendations for reimbursement from the Canadian Agency of Drugs and Technology ...
Posted by Michael Wonder on 13 Jan 2021
CADTH publishes initial recommendation for nivolumab for NSCLC
9 January 2021 - The pERC has conditionally recommended the reimbursement of nivolumab when used in combination with ipilimumab and ...
Posted by Michael Wonder on 13 Jan 2021
CADTH publishes initial pCODR recommendation for entrectinib
9 January 2021 - pERC has conditionally recommended the reimbursement of entrectinib for the first-line treatment of patients with ROS1 positive ...
Posted by Michael Wonder on 29 Oct 2020
CADTH publishes final recommendation for Blincyto
29 October 2020 - The pERC final recommendation is based on a reconsideration of the initial recommendation and feedback from eligible ...
Posted by Michael Wonder on 21 Jan 2019
Will price be a barrier to new cancer immunotherapy?
19 January 2019 - Advisory group CADTH recommends no funding for new CAR-T therapy until drug company lowers cost. ...
Posted by Michael Wonder on 05 Nov 2018
CADTH publishes initial recommendation for Tagrisso
5 November 2018 - CADTH has published its initial recommendation on the use of osimertinib mesylate for the first-line treatment ...
Posted by Michael Wonder on 05 Nov 2018
CADTH publishes initial recommendation for Lenvima
5 November 2018 - CADTH has published its initial recommendation on the use of lenvatinib mesylate in combination with everolimus ...
Posted by Michael Wonder on 08 Jul 2018
CADTH publishes initial pERC recommendation for Roche's alectinib hydrochloride
6 July 2018 - The outcome relates to the use of alectinib hydrochloride (Alecensaro) for the first-line treatment of patients ...
Posted by Michael Wonder on 25 Sep 2017
First-in-class BRCA-positive ovarian cancer medicine Lynparza (olaparib) receives positive pan-Canadian Oncology Drug Review recommendation for provincial reimbursement
21 September 2017 - This marks an important first step towards providing Canadian women with access to this treatment. ...